Journal Article
. 2016 Aug; 197(6):2509-21.
doi: 10.4049/jimmunol.1502659.

Immunotherapy Expands and Maintains the Function of High-Affinity Tumor-Infiltrating CD8 T Cells In Situ

Amy E Moran 1 Fanny Polesso 2 Andrew D Weinberg 2 
  • PMID: 27503208
  •     63 References
  •     13 citations


Cancer cells harbor high-affinity tumor-associated Ags capable of eliciting potent antitumor T cell responses, yet detecting these polyclonal T cells is challenging. Therefore, surrogate markers of T cell activation such as CD69, CD44, and programmed death-1 (PD-1) have been used. We report in this study that in mice, expression of activation markers including PD-1 is insufficient in the tumor microenvironment to identify tumor Ag-specific T cells. Using the Nur77GFP T cell affinity reporter mouse, we highlight that PD-1 expression can be induced independent of TCR ligation within the tumor. Given this, we characterized the utility of the Nur77GFP model system in elucidating mechanisms of action of immunotherapies independent of PD-1 expression. Coexpression of Nur77GFP and OX40 identifies a polyclonal population of high-affinity tumor-associated Ag-specific CD8(+) T cells, which produce more IFN-γ in situ than OX40 negative and doubles in quantity with anti-OX40 and anti-CTLA4 mAb therapy but not with anti-PD-1 or programmed death ligand-1. Moreover, expansion of these high-affinity CD8 T cells prolongs survival of tumor-bearing animals. Upon chronic stimulation in tumors and after adoptive cell therapy, CD8 TCR signaling and Nur77GFP induction is impaired, and tumors progress. However, this can be reversed and overall survival significantly enhanced after adoptive cell therapy with agonist OX40 immunotherapy. Therefore, we propose that OX40 agonist immunotherapy can maintain functional TCR signaling of chronically stimulated tumor-resident CD8 T cells, thereby increasing the frequency of cytotoxic, high-affinity, tumor-associated Ag-specific cells.

Immunological memory and protective immunity: understanding their relation.
R Ahmed, D Gray.
Science, 1996 Apr 05; 272(5258). PMID: 8600537
Highly Cited. Review.
Murine thymic selection quantified using a unique method to capture deleted T cells.
Gretta L Stritesky, Yan Xing, +5 authors, Kristin A Hogquist.
Proc Natl Acad Sci U S A, 2013 Mar 15; 110(12). PMID: 23487759    Free PMC article.
Highly Cited.
T cell receptor signal strength in Treg and iNKT cell development demonstrated by a novel fluorescent reporter mouse.
Amy E Moran, Keli L Holzapfel, +4 authors, Kristin A Hogquist.
J Exp Med, 2011 May 25; 208(6). PMID: 21606508    Free PMC article.
Highly Cited.
Quiescence of Memory CD8(+) T Cells Is Mediated by Regulatory T Cells through Inhibitory Receptor CTLA-4.
Vandana Kalia, Laura Anne Penny, +2 authors, Surojit Sarkar.
Immunity, 2015 Jun 18; 42(6). PMID: 26084026
Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.
Y Agata, A Kawasaki, +4 authors, T Honjo.
Int Immunol, 1996 May 01; 8(5). PMID: 8671665
Highly Cited.
Mutant MHC class II epitopes drive therapeutic immune responses to cancer.
Sebastian Kreiter, Mathias Vormehr, +12 authors, Ugur Sahin.
Nature, 2015 Apr 23; 520(7549). PMID: 25901682    Free PMC article.
Highly Cited.
OX40 promotes Bcl-xL and Bcl-2 expression and is essential for long-term survival of CD4 T cells.
P R Rogers, J Song, +2 authors, M Croft.
Immunity, 2001 Sep 25; 15(3). PMID: 11567634
Highly Cited.
Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection.
Joseph N Blattman, E John Wherry, +2 authors, Rafi Ahmed.
J Virol, 2009 Feb 13; 83(9). PMID: 19211743    Free PMC article.
Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine.
D Berd, H C Maguire, M J Mastrangelo, G Murphy.
Cancer Immunol Immunother, 1994 Sep 01; 39(3). PMID: 7923243
A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.
T Wölfel, M Hauer, +7 authors, D Beach.
Science, 1995 Sep 01; 269(5228). PMID: 7652577
Highly Cited.
OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer.
Ryan Montler, R Bryan Bell, +8 authors, Andrew Weinberg.
Clin Transl Immunology, 2016 May 20; 5(4). PMID: 27195113    Free PMC article.
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
P G Coulie, F Lehmann, +4 authors, T Boon.
Proc Natl Acad Sci U S A, 1995 Aug 15; 92(17). PMID: 7644523    Free PMC article.
Highly Cited.
T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases.
Thorsten R Mempel, Sarah E Henrickson, Ulrich H Von Andrian.
Nature, 2004 Jan 09; 427(6970). PMID: 14712275
Highly Cited.
PD-1 induction through TCR activation is partially regulated by endogenous TGF-β.
Raja Rekik, Nadia Belhadj Hmida, +3 authors, Melika Ben Ahmed.
Cell Mol Immunol, 2014 Nov 05; 12(5). PMID: 25363526    Free PMC article.
Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control.
Michael Y Gerner, Lynn M Heltemes-Harris, Brian T Fife, Matthew F Mescher.
J Immunol, 2013 Jun 28; 191(3). PMID: 23804712    Free PMC article.
Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.
Naiyer A Rizvi, Matthew D Hellmann, +21 authors, Timothy A Chan.
Science, 2015 Mar 15; 348(6230). PMID: 25765070    Free PMC article.
Highly Cited.
Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer.
Eric Tran, Simon Turcotte, +10 authors, Steven A Rosenberg.
Science, 2014 May 09; 344(6184). PMID: 24812403    Free PMC article.
Highly Cited.
Endogenous antigen tunes the responsiveness of naive B cells but not T cells.
Julie Zikherman, Ramya Parameswaran, Arthur Weiss.
Nature, 2012 Aug 21; 489(7414). PMID: 22902503    Free PMC article.
Highly Cited.
Antigen-independent activation of naive and memory resting T cells by a cytokine combination.
D Unutmaz, P Pileri, S Abrignani.
J Exp Med, 1994 Sep 01; 180(3). PMID: 8064232    Free PMC article.
Highly Cited.
Complete but curtailed T-cell response to very low-affinity antigen.
Dietmar Zehn, Sarah Y Lee, Michael J Bevan.
Nature, 2009 Feb 03; 458(7235). PMID: 19182777    Free PMC article.
Highly Cited.
TGFβ Is a Master Regulator of Radiation Therapy-Induced Antitumor Immunity.
Claire Vanpouille-Box, Julie M Diamond, +5 authors, Sandra Demaria.
Cancer Res, 2015 Apr 11; 75(11). PMID: 25858148    Free PMC article.
Highly Cited.
Human T lymphocyte adhesion to endothelial cells and transendothelial migration. Alteration of receptor use relates to the activation status of both the T cell and the endothelial cell.
N Oppenheimer-Marks, L S Davis, P E Lipsky.
J Immunol, 1990 Jul 01; 145(1). PMID: 1972715
A sharp T-cell antigen receptor signaling threshold for T-cell proliferation.
Byron B Au-Yeung, Julie Zikherman, +6 authors, Arthur Weiss.
Proc Natl Acad Sci U S A, 2014 Aug 20; 111(35). PMID: 25136127    Free PMC article.
CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs.
Lawrence R Shiow, David B Rosen, +5 authors, Mehrdad Matloubian.
Nature, 2006 Mar 10; 440(7083). PMID: 16525420
Highly Cited.
Inflammation and cancer.
Lisa M Coussens, Zena Werb.
Nature, 2002 Dec 20; 420(6917). PMID: 12490959    Free PMC article.
Highly Cited. Review.
Cutting edge: re-evaluating the in vivo cytokine responses of CD8+ T cells during primary and secondary viral infections.
Fei Liu, J Lindsay Whitton.
J Immunol, 2005 May 10; 174(10). PMID: 15879085
Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen.
L L Lanier, D W Buck, +4 authors, J H Phillips.
J Exp Med, 1988 May 01; 167(5). PMID: 3259252    Free PMC article.
Cutting edge: naive T cells masquerading as memory cells.
K Murali-Krishna, R Ahmed.
J Immunol, 2000 Aug 05; 165(4). PMID: 10925249
Highly Cited.
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100.
Y Zhai, J C Yang, +5 authors, S A Rosenberg.
J Immunother, 1997 Jan 01; 20(1). PMID: 9101410    Free PMC article.
Induction of bystander T cell proliferation by viruses and type I interferon in vivo.
D F Tough, P Borrow, J Sprent.
Science, 1996 Jun 28; 272(5270). PMID: 8658169
Highly Cited.
OX40 and Bcl-xL promote the persistence of CD8 T cells to recall tumor-associated antigen.
Aihua Song, Xiaohong Tang, Kate Marie Harms, Michael Croft.
J Immunol, 2005 Sep 09; 175(6). PMID: 16148096
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand.
W W Overwijk, A Tsung, +8 authors, N P Restifo.
J Exp Med, 1998 Jul 22; 188(2). PMID: 9670040    Free PMC article.
Highly Cited.
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.
Paul F Robbins, Yong-Chen Lu, +9 authors, Steven A Rosenberg.
Nat Med, 2013 May 07; 19(6). PMID: 23644516    Free PMC article.
Highly Cited.
Rapid on/off cycling of cytokine production by virus-specific CD8+ T cells.
M K Slifka, F Rodriguez, J L Whitton.
Nature, 1999 Sep 15; 401(6748). PMID: 10485708
Tumor masses support naive T cell infiltration, activation, and differentiation into effectors.
Elizabeth D Thompson, Hilda L Enriquez, Yang-Xin Fu, Victor H Engelhard.
J Exp Med, 2010 Jul 28; 207(8). PMID: 20660615    Free PMC article.
Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway.
Magdalena J Polanczyk, Corwyn Hopke, Arthur A Vandenbark, Halina Offner.
J Neurosci Res, 2006 May 06; 84(2). PMID: 16676326
PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.
Alena Gros, Paul F Robbins, +13 authors, Steven A Rosenberg.
J Clin Invest, 2014 Mar 29; 124(5). PMID: 24667641    Free PMC article.
Highly Cited.
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
William L Redmond, Michael J Gough, Andrew D Weinberg.
Eur J Immunol, 2009 Aug 13; 39(8). PMID: 19672905    Free PMC article.
Inflammation and cancer: back to Virchow?
F Balkwill, A Mantovani.
Lancet, 2001 Mar 07; 357(9255). PMID: 11229684
Highly Cited. Review.
Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts.
D J Paterson, W A Jefferies, +4 authors, A F Williams.
Mol Immunol, 1987 Dec 01; 24(12). PMID: 2828930
Highly Cited.
Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
A D Weinberg, M M Rivera, +7 authors, J Shields.
J Immunol, 2000 Feb 05; 164(4). PMID: 10657670
Highly Cited.
IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity.
Seigo Terawaki, Shunsuke Chikuma, +4 authors, Tasuku Honjo.
J Immunol, 2011 Jan 26; 186(5). PMID: 21263073
Highly Cited.
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells.
Jason R Lees, Bridget Charbonneau, +4 authors, Timothy L Ratliff.
Immunology, 2006 Jan 21; 117(2). PMID: 16423061    Free PMC article.
Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma.
Nienke van Rooij, Marit M van Buuren, +14 authors, Ton N Schumacher.
J Clin Oncol, 2013 Sep 18; 31(32). PMID: 24043743    Free PMC article.
Highly Cited.
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.
W R Godfrey, F F Fagnoni, +2 authors, E G Engleman.
J Exp Med, 1994 Aug 01; 180(2). PMID: 7913952    Free PMC article.
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses.
Carl E Ruby, William L Redmond, Daniel Haley, Andrew D Weinberg.
Eur J Immunol, 2006 Dec 22; 37(1). PMID: 17183611
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
T cell receptor antagonist peptides induce positive selection.
K A Hogquist, S C Jameson, +3 authors, F R Carbone.
Cell, 1994 Jan 14; 76(1). PMID: 8287475
Highly Cited.
The common gamma-chain cytokines IL-2, IL-7, IL-15, and IL-21 induce the expression of programmed death-1 and its ligands.
Audrey L Kinter, Emily J Godbout, +4 authors, Anthony S Fauci.
J Immunol, 2008 Nov 05; 181(10). PMID: 18981091
Highly Cited.
Helper T cells infiltrating human renal cell carcinomas have the phenotype of activated memory-like T lymphocytes.
R B Alexander, E B Fitzgerald, +4 authors, S A Rosenberg.
J Immunother Emphasis Tumor Immunol, 1995 Jan 01; 17(1). PMID: 7728304
Cutting edge: CD69 interference with sphingosine-1-phosphate receptor function regulates peripheral T cell retention.
Laura K Mackay, Asolina Braun, +5 authors, Thomas Gebhardt.
J Immunol, 2015 Jan 28; 194(5). PMID: 25624457
Highly Cited.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
Type I interferon-mediated stimulation of T cells by CpG DNA.
S Sun, X Zhang, D F Tough, J Sprent.
J Exp Med, 1998 Dec 22; 188(12). PMID: 9858519    Free PMC article.
Highly Cited.
Immunogenicity of somatic mutations in human gastrointestinal cancers.
Eric Tran, Mojgan Ahmadzadeh, +10 authors, Steven A Rosenberg.
Science, 2015 Nov 01; 350(6266). PMID: 26516200    Free PMC article.
Highly Cited.
Costimulation of CD8 T cell responses by OX40.
Pratima Bansal-Pakala, Beth S Halteman, Mary Huey-Yu Cheng, Michael Croft.
J Immunol, 2004 Apr 07; 172(8). PMID: 15067059
Transcriptional analysis of clonal deletion in vivo.
Troy A Baldwin, Kristin A Hogquist.
J Immunol, 2007 Jul 10; 179(2). PMID: 17617574
Memory CD8+ T cell differentiation: initial antigen encounter triggers a developmental program in naïve cells.
S M Kaech, R Ahmed.
Nat Immunol, 2001 Apr 27; 2(5). PMID: 11323695    Free PMC article.
Highly Cited.
Nuclear hormone receptors in T lymphocytes.
Astar Winoto, Dan R Littman.
Cell, 2002 May 02; 109 Suppl. PMID: 11983153
Thymic OX40 expression discriminates cells undergoing strong responses to selection ligands.
Mark Klinger, Joong Kyu Kim, +3 authors, Nigel Killeen.
J Immunol, 2009 Apr 04; 182(8). PMID: 19342632    Free PMC article.
Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.
A Kotani, T Ishikawa, +4 authors, T Uchiyama.
Blood, 2001 Nov 08; 98(10). PMID: 11698307
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade.
Marcella Fassò, Rebecca Waitz, +5 authors, James P Allison.
Proc Natl Acad Sci U S A, 2008 Feb 28; 105(9). PMID: 18303116    Free PMC article.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
OX40 is a potent immune-stimulating target in late-stage cancer patients.
Brendan D Curti, Magdalena Kovacsovics-Bankowski, +20 authors, Andrew D Weinberg.
Cancer Res, 2013 Nov 02; 73(24). PMID: 24177180    Free PMC article.
Highly Cited.
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
Nusrat Jahan, Hammad Talat, William T Curry.
Neuro Oncol, 2017 Oct 11; 20(1). PMID: 29016879    Free PMC article.
Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma.
Timothy M Nywening, Brian A Belt, +12 authors, David C Linehan.
Gut, 2017 Dec 03; 67(6). PMID: 29196437    Free PMC article.
Highly Cited.
An OX40/OX40L interaction directs successful immunity to hepatitis B virus.
Jean Publicover, Anuj Gaggar, +15 authors, Jody L Baron.
Sci Transl Med, 2018 Mar 23; 10(433). PMID: 29563320    Free PMC article.
Tumor cure by radiation therapy and checkpoint inhibitors depends on pre-existing immunity.
Marka R Crittenden, Lauren Zebertavage, +7 authors, Michael J Gough.
Sci Rep, 2018 May 05; 8(1). PMID: 29725089    Free PMC article.
Immune targets in the tumor microenvironment treated by radiotherapy.
Omer M Ozpiskin, Lu Zhang, Jian Jian Li.
Theranostics, 2019 Mar 15; 9(5). PMID: 30867826    Free PMC article.
Highly Cited. Review.
Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies.
Roheena Z Panni, John M Herndon, +13 authors, David G DeNardo.
Sci Transl Med, 2019 Jul 05; 11(499). PMID: 31270275    Free PMC article.
Highly Cited.
New pathways in immune stimulation: targeting OX40.
Carolina Alves Costa Silva, Francesco Facchinetti, Bertrand Routy, Lisa Derosa.
ESMO Open, 2020 May 12; 5(1). PMID: 32392177    Free PMC article.
Anti-neoplastic and immunomodulatory potency of co-treatment based on bovine lactoferrin and/or muramyl dipeptide in tumor-bearing mice.
Hany M Ibrahim, Azza H Mohamed, +2 authors, Dalia S Morsi.
Toxicol Res (Camb), 2020 May 23; 9(2). PMID: 32440345    Free PMC article.
Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.
Jonathan P O Hebb, Adriane R Mosley, +4 authors, Dean W Felsher.
Cancer Immunol Immunother, 2017 Sep 15; 67(1). PMID: 28905118    Free PMC article.
Neoadjuvant anti-OX40 (MEDI6469) therapy in patients with head and neck squamous cell carcinoma activates and expands antigen-specific tumor-infiltrating T cells.
Rebekka Duhen, Carmen Ballesteros-Merino, +12 authors, Andrew D Weinberg.
Nat Commun, 2021 Feb 18; 12(1). PMID: 33594075    Free PMC article.
Potentiating the Antitumor Activity of Cytotoxic T Cells via the Transmembrane Domain of IGSF4 That Increases TCR Avidity.
Hye-Ran Kim, Jeong-Su Park, +3 authors, Chang-Duk Jun.
Front Immunol, 2021 Feb 19; 11. PMID: 33597944    Free PMC article.
The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors.
Tiffany C Blair, Alejandro F Alice, +2 authors, Michael J Gough.
Front Oncol, 2021 May 11; 11. PMID: 33968757    Free PMC article.
Androgen receptor activity in T cells limits checkpoint blockade efficacy.
Xiangnan Guan, Fanny Polesso, +12 authors, Amy E Moran.
Nature, 2022 Mar 25;. PMID: 35322234